0001104659-22-023774.txt : 20220215 0001104659-22-023774.hdr.sgml : 20220215 20220215160237 ACCESSION NUMBER: 0001104659-22-023774 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210716 FILED AS OF DATE: 20220215 DATE AS OF CHANGE: 20220215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Meek David D. CENTRAL INDEX KEY: 0001555337 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38670 FILM NUMBER: 22639142 MAIL ADDRESS: STREET 1: 3000 KENT AVENUE; SUITE A1-100 CITY: WEST LAFAYETTE STATE: IN ZIP: 47906 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Entasis Therapeutics Holdings Inc. CENTRAL INDEX KEY: 0001724344 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824592913 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 GATEHOUSE DRIVE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 810-0120 MAIL ADDRESS: STREET 1: 35 GATEHOUSE DRIVE CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Entasis Therapeutics Ltd DATE OF NAME CHANGE: 20171204 4 1 tm226724-5_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-07-16 0 0001724344 Entasis Therapeutics Holdings Inc. ETTX 0001555337 Meek David D. C/O ENTASIS THERAPEUTICS HOLDINGS INC., 35 GATEHOUSE DRIVE WALTHAM MA 02451 1 0 0 0 Stock Option (Right to Buy) 6.12 2021-07-16 4 D 0 15000 D 2029-06-18 Common Stock 15000 0 D Stock Option (Right to Buy) 2.44 2021-07-16 4 A 0 11538 A 2031-07-15 Common Stock 11538 11538 D Stock Option (Right to Buy) 6.12 2021-07-16 4 D 0 7500 D 2029-06-18 Common Stock 7500 0 D Stock Option (Right to Buy) 2.44 2021-07-16 4 A 0 5769 A 2031-07-15 Common Stock 5769 5769 D The option provided for vesting as follows: The shares subject to this option will vest in equal monthly installments over the three years following the date of grant, subject to the Reporting Person's continued service through each such vesting date. On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 shares of issuer's common stock granted to the Reporting Person on June 19, 2019. In exchange, the Reporting Person received a replacement option for 11,538 shares of issuer's common stock, having an exercise price of $2.44 per share. The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date. The option provided for vesting as follows: The shares subject to this option will vest in equal monthly installments over the 12 months following the date of grant, provided that the option will in any case be fully vested on the date of the next annual stockholder meeting, subject to the Reporting Person's continued service through each such vesting date. On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 7,500 shares of issuer's common stock granted to the Reporting Person on June 19, 2019. In exchange, the Reporting Person received a replacement option for 5,769 shares of issuer's common stock, having an exercise price of $2.44 per share. The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date. Elizabeth M. Keiley as Attorney-in-Fact for David Meek 2022-02-14